NIKKEI 225
38,164.39 +202.59 (+0.53%) HANG SENG
16,469.29 +217.45 (+1.34%) CRUDE OIL
82.82 +0.13 (+0.16%) GOLD FUTURES
2,390.70 +2.30 (+0.10%) DOW
37,753.31 -45.66 (-0.12%) Bitcoin GBP
49,642.61 -1,785.56 (-3.47%)
PDS Biotechnology Corporation (PDSB)
After hours:
| Previous close | 2.8000 |
| Open | 2.8400 |
| Bid | 2.7000 x 300 |
| Ask | 2.7300 x 100 |
| Day's range | 2.6800 - 2.8400 |
| 52-week range | 2.6800 - 10.2700 |
| Volume | |
| Avg. volume | 924,617 |
| Market cap | 102.519M |
| Beta (5Y monthly) | 1.72 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
Unique mechanism of action of the combination of PDS01ADC and Versamune® results in 3-year survival of 75% and 75% overall response rate in advanced head and neck cancer trial As a result, Company to focus late-stage clinical strategy on triple combination of PDS01ADC, PDS0101 (Versamune® HPV) and KEYTRUDA® in advanced head and neck cancer Strong safety profile of IL-12 fused antibody drug conjugate (PDS01ADC) demonstrated to date with data generated in >300 cancer patients; Versamune® HPV teste
- GlobeNewswire
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell-activating platforms, today announced that the Company will provide a business update and release financial results for the year ended December 31, 2023, on Wednesday, March 27, 2024. Followi
- GlobeNewswire
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants Patent for composition of matter and use of Infectimune® based influenza vaccines granted in the United States PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targe
